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Objective: In active infective endocarditis the need for operating simultaneously on the aortic and mitral valves is
frequent. There are no studies in the literature documenting long-term outcomes of double valve surgery for active
endocarditis.
Methods: Ninety patients underwent double valve surgery for active endocarditis over a 26-year period (mean
age, 53  16 years; 71% male patients). Prosthetic endocarditis was seen in 32 patients. Staphylococcus species
was isolated in 29%. Forty-six (51%) patients had abscesses. Surgical intervention consisted of valve repair or
replacement with limited infection or radical resection, patch reconstruction, and valve replacement for abscesses.
Mean follow-up was 5.9  4.7 years (range, 0–18 years) and was complete.
Results: There were 14 (15.6%) in-hospital deaths and 29 (32.2%) late deaths. Overall survival at 5, 7, and 10
years was 68%  5%, 59%  6%, and 49%  6%, respectively, and was reduced in those undergoing oper-
ations for prosthetic compared with native endocarditis (7-year survival, 39%  9% vs 71%  7%; P< .001).
Freedom from recurrent endocarditis was 84%  5% at 10 years. Freedom from reoperation was 91%  4% at
10 years. Event-free survival at 7 and 10 years was 60% 6% and 47% 7%, respectively. No difference was
observed between the native and prosthetic groups for recurrent endocarditis, late reoperation, or event-free sur-
vival. Prosthetic endocarditis, increasing age, preoperative shock, and diabetes mellitus were independent predic-
tors of death from all causes.
Conclusions: Double valve surgery for active endocarditis remains technically challenging and associated with
significant morbidity and mortality perioperatively and in the longer term. Outcomes are worse in those who have
prosthetic valve endocarditis.Extensive tissue destruction and abscess formation in pa-
tients with infective endocarditis can make surgical interven-
tion for infective endocarditis especially difficult. Radical
debridement and reconstruction form the cornerstone of sur-
gical management in infective endocarditis.1-3 The complex-
ity of the operation is markedly increased when more than 1
valve is involved. Double valve surgery (aortic and mitral)
for active endocarditis is second in frequency only to iso-
lated aortic valve involvement.4 There have been no studies
that have documented long-term outcomes of double valve
surgery in patients who have active infective endocarditis.
We therefore undertook this study.
MATERIALS AND METHODS
A review of the Toronto General Hospital cardiac surgery database from
1979 to 2004 revealed 90 patients who had undergone surgical intervention
for active endocarditis in which both the mitral and aortic valves underwent
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doi:10.1016/j.jtcvs.2008.11.049The Journal of Thoracic andsurgical intervention. Either 1 or both valves had active infection. We in-
cluded patients undergoing double valve surgery with 1 actively infected
valve and a second diseased but noninfected valve because the pathology
encountered and the operation required are complex. Patients with remote
or healed endocarditis were excluded. Patients with additional endocarditis
involvement of the right-sided valves or in whom further surgical interven-
tion was required to the right-sided valves were also excluded. Where nec-
essary, relevant information was also derived by reviewing hospital medical
records. Approval was obtained from the ethics review board of the hospital.
Indications for surgical intervention were 1 or more of the following: shock,
14 (16%); congestive cardiac failure, 64 (72%); cerebral embolism, 26
(29%); and perivalvular abscess, 46 (51%). Table 1 shows the clinical char-
acteristics of the patients.
Infecting Organisms
Data for the infecting organism were available for 75 patients. Staphylo-
coccus species was most commonly encountered: Staphylococcus aureus in
14 (16%) patients and Staphylococcus epidermidis in 12 (13%) patients.
Streptococcus viridans was found in 13 (14%) patients, Enterococcus fae-
calis was found in 8 (9%) patients, other Streptococcus species were found
in 13 (14%) patients, Pseudomonas species were found in 2 (2%) patients,
other bacteria were found in 4 (4%) patients, and culture-negative endocar-
ditis was found in 9 (10%) patients.
Operative Procedures
The extent of tissue destruction from the endocarditis was assessed. Where
infection was limited to the leaflets of the native or prosthetic valve, simple
replacement or repair, if feasible, in the case of the mitral valve, was per-
formed. Where infection had extended to or beyond the annulus, surgical
intervention consisted of radical resection of all infected tissue, followed by
reconstruction as necessary with valve replacement, as has been previouslyCardiovascular Surgery c Volume 138, Number 1 69
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CI ¼ confidence interval
HR ¼ hazard ratio
described.1-3,5 Pre-existing mitral and aortic valve pathology is described
in Table 2. Operative data are summarized in Table 3. The average cardio-
pulmonary bypass time was 158  60 minutes with a crossclamp time of
124  42 minutes.
Follow-up
All patients were reviewed annually by the referring cardiologist, and data
were collected prospectively. Our dedicated research personnel verified all
cardiac events and maintained a comprehensive database. The mean fol-
low-up was 5.9  4.7 years (range, 0–18 years) and was complete.
Statistics
Continuous variables were reported as the mean  standard deviation.
All data analyses were performed with SAS 9.1 Software (SAS Institute,
Inc, Cary, NC). Fisher’s exact or c2 tests were used to evaluate categorical
variables univariately and were reported as frequencies. Student’s t test was
used to analyze continuous variables that had normal distribution, and the
Wilcoxon rank test was used for variables that had nonparametric distribu-
tion. The Kaplan–Meier method was used to calculate estimates for long-
term survival, freedom from late reoperation, freedom from recurrent endo-
carditis, and event-free survival. Event-free survival was defined as the free-
dom from thromboembolism (including stroke), valve thrombosis,
hemolysis, structural valve dysfunction, perivalvular leak, major bleeding
event, endocarditis, reoperation, and death in hospital survivors. In line
with the recent Society of Thoracic Surgeons guidelines on reporting out-
comes after valve surgery,6 we have defined operative mortality as death
within 90 days of the operation. All preoperative variables with a univariate
P value of less than .25 or those judged to be clinically important were sub-
mitted to the multivariable model for Cox regression analysis to determine
the independent predictors of operative and late deaths.
RESULTS
Eighty-one patients had active endocarditis involving
both the aortic and mitral valves. In 9 patients there was ac-
tive infection of one valve, and the other valve also under-
went surgical intervention for the following reasons:
dilated mitral annulus, 2; myxomatous or prolapsing mitral
valve, 2; rheumatic mitral valve, 1; ischemic mitral valve,
1; rheumatic aortic valve, 1; and prolapsing aortic valve, 2.
There were 14 (16%) operative deaths (death within 90
days). Operative mortalities are summarized for the various
subgroups in Table 4. Although cause of death was usually
multifactorial, the main causes were as follows: cardiogenic
shock, 5; cardiac arrest, 1; stroke, 3; multiorgan failure, 3;
excessive postoperative hemorrhage, 1; and failure to
wean from cardiopulmonary bypass, 1. In this group, of
the significant factors identified in the univariate analysis
for operative deaths, prosthetic endocarditis was present in
9 patients, diabetes in 5 patients, hypertension in 6 patients,
and preoperative shock in 7 patients. Of borderline statistical
significance was female sex (P ¼ .058); 7 patients were
female. Ten patients had paravalvular abscesses. Double70 The Journal of Thoracic and Cardiovascular SurgTABLE 1. Clinical characteristics
No. Percentage
Mean age (y) 53.3  15.8
Male sex 64 71
Comorbid conditions
Diabetes mellitus 13 15
Hypertension 19 22
Chronic obstructive lung disease 7 8
Renal failure 20 22
Recent myocardial infarction (<30 d) 2 2
Recent stroke or transient ischemic
attack (<30 d)
26 29
Peripheral vascular disease 4 5
New York Heart Association class
I 3 3
II 4 5
III 6 7
IV 76 85
Preoperative rhythm
Sinus rhythm 69 77
Atrial fibrillation 21 23
Cardiogenic or septic shock 14 16
Congestive cardiac failure 64 72
Endocarditis
Native 58 64
Prosthetic 32 36
Previous cardiac surgery 34 38
Coronary artery bypass 5 6
Aortic valve replacement 27 30
Aortic valve repair 1 1
Mitral valve repair 1 1
Mitral valve replacement 18 20
Tricuspid valve repair 0
Aortic annular enlargement 27 35
Annulus 12 15
Sinuses 4 5
Both 11 14
Left ventricular ejection fraction
40% 71 85
<40% 13 16
Timing of operation
Elective/same hospitalization 35 42
Urgent/emergency 49 58
TABLE 2. Pre-existing valve pathology
No. Percentage
Aortic valve pathology
Bicuspid 15 17
Rheumatic 8 9
Calcific degeneration 7 8
Prosthetic dysfunction 16 18
Mitral valve pathology
Rheumatic 12 13
Myxomatous 5 6
Ischemic 1 1
Prosthetic dysfunction 11 12
Annular dilatation 2 2ery c July 2009
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fibrous body and aortic root replacement were not associated
with increased operative mortality. When examining for any
change over time, we found no difference in operative mor-
tality between the first and second halves of the study (17%
for 1979–1994 vs 14% for 1995–2004, P ¼ .69).
The mean stay in the intensive care unit was 7.9  18.3
days (median, 3 days), with mean ventilation times of 4.4
 12 days (median, 1 day). Postoperative complications
are summarized in Table 5. Mean hospital stay was 19 
15 days (median, 16 days). Six patients required repeat
operations during the same admission, 5 for technical com-
plications: mitral annulus patch dehiscence, 2; Gerbode-type
ventricular septal defect, 1; ascending aortic false aneurysm,
1; aortic sinus fistula to the pulmonary artery, 1; and recur-
rent endocarditis, 1. There was 1 death associated with these
repeat early operations. There were no cases of deep sternal
wound infection.
A further 29 patients died during follow-up. There were 10
valve-related deaths (recurrent endocarditis in 6, perivalvular
leak in 1, anticoagulation-related hemorrhage in 1, cardiac
arrest in 1, and sudden death in 1) and a further 10 cardiac
deaths (congestive heart failure in 6 and myocardial infarc-
tion in 4). There were 9 noncardiac deaths (cancer in 6, renal
TABLE 3. Operative data
No. Percentage
Mitral valve operation performed
Mitral valve repair 25 28
Mitral valve replacement 65 72
Mitral valve prosthesis used
Mechanical 46 51
Bioprosthesis 19 21
Repair ring/band 7 8
Mitral valve annulus reconstruction 29 29
Autologous pericardium 8 9
Bovine pericardium 18 20
Chordal preservation in mitral valve replacement
Posterior only 10 11
Anterior and posterior 10 11
Polytetrafluoroethylene* sutures 14 16
Aortic valve operation performed
Aortic valve replacement 78 87
Tissue prosthesis 27 30
Mechanical prosthesis 51 57
Aortic root replacement 12 13
Composite mechanical graft 5 6
Freestyle stentless 2 2
Composite tailored tissue graft 1 1
Homograft 4 4
Reconstruction of intervalvular fibrous body 25 28
Concomitant procedures
Coronary artery bypass grafting 12 13
Replacement of supracoronary ascending aorta 2 2
Abscess 46 51.1
*Gore-Tex sutures; W. L. Gore & Associates, Inc, Newark, Del.The Journal of Thoracic andfailure in 2, and bowel ischemia in 1). Survival was 68% 
5%, 59%  6%, and 49%  6% at 5, 7, and 10 years,
respectively (Figure 1). Survival was greater in those under-
going operations for native valve endocarditis than for pros-
thetic valve endocarditis (7-year survival, 71%  6% vs
39% 9%, respectively;P<.001; Figure 2). Cox regression
analysis identified diabetes (hazard ratio [HR], 4.91; 95%
confidence interval [CI], 2.15–11.23; P< .001), prosthetic
valve endocarditis (HR, 4.1; 95% CI, 1.92–8.56; P< .001),
preoperative shock (HR, 2.63; 95% CI, 1.1–6.3; P ¼ .03),
and increased age (HR, 1.3; 95% CI, 1.14–1.54; P< .001)
as independent predictors of death from all causes. Double
valve replacement with reconstruction of the intervalvular
fibrous body, a sizeable surgical undertaking, and aortic
root replacement were not predictors of late death.
TABLE 4. Operative mortalities in various subgroups
Variable No. Mortality (%) P value
Patient characteristics
Native endocarditis 58 8.6
Prosthetic endocarditis 32 28.1 .015
Female sex 26 26.9 .058
Diabetes 13 38.5 .015
Hypertension 19 31.6 .02
Preoperative shock 14 50 .0001
Preoperative renal failure 20 20 .5
Preoperative stroke,
transient ischemic attack
26 23.1 .22
Preoperative atrial fibrillation 21 4.8 .17
Preoperative congestive
heart failure
64 17.2 .75
Preoperative syncope 5 40 .178
Paravalvular abscess 46 21.7 .15
Staphylococcus aureus 14 14.3 1
Ejection fraction<40% 13 15.4 1
NYHA class
I/II/III 13 7.69
IV 76 17.1 .68
Timing of operation
Elective/same hospitalization 35 8.6
Urgent/emergency 49 18.4 .34
Any redo operation 34 26.5 .026
Previous mitral valve surgery 19 31.6 .03
Previous aortic valve surgery 28 25 .097
Operative factors
Mitral valve chordal preservation 20 15 1
Mitral valve annulus reconstruction 26 23.1 .24
Mitral valve repair 25 4 .1
Mitral valve replacement 65 20
Aortic valve prosthesis
Tissue 34 14.7
Mechanical 56 16.1 .86
Double valve replacement with
reconstruction of intervalvular
fibrous body
25 20 .47
Aortic root replacement 12 8.3 1
NYHA, New York Heart Association.Cardiovascular Surgery c Volume 138, Number 1 71
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significant factors associated with operative and late deaths,
prosthetic endocarditis was present in 2 patients, and preoper-
ative shock was present in 2 patients. Paravalvular abscess was
present in 6 patients at the first operation for endocarditis. Four
had early endocarditis (1 year). The infecting organism was
different from the original episode in 5 patients and the same in
1 patient, and in 4 patients this information was missing be-
cause the patients were readmitted to other hospitals. Three
of these patients underwent reoperations and survived. Of
the 7 patients managed conservatively with antibiotic therapy,
there was only 1 survivor. Of the 6 endocarditis-related deaths,
1 was an intravenous drug abuser. Freedom from recurrent en-
docarditis overall was 88% 4% at 5 years and 84% 5%
at 10 years. There was no significant difference in freedom
from recurrence of endocarditis between the native and pros-
thetic endocarditis groups (7-year freedom from endocarditis
was 80% 6% for native valve and 95% 5% for prosthetic
endocarditis, P ¼ .16).
Late morbidity events are summarized in Table 6. There
were no instances of valve hemolysis. There were 10 late re-
TABLE 5. Postoperative complications
Complication No.
Associated
mortality (%) P value
Reopening
For bleeding 8 25 .61
For tamponade 3 0
Arrest 1 100
Redo operation 6 17 1
Stroke 5 80 .002
Intraoperative 3
Postoperative 2
Renal failure 7 57.1 .012
Sepsis 4 0 1
Pulmonary complications 22 9.1 .5
Insertion of permanent
pacemaker
12 16.7 1
Need for inotropes 68 17.7 .5
FIGURE 1. Long-term actuarial survival for all patients.72 The Journal of Thoracic and Cardiovascular Surgoperations, for which there were no operative mortalities for
patients undergoing reoperation. In one of the 3 patients re-
quiring a reoperation for paravalvular leak, mitral annulus
patch reconstruction with bovine pericardium had been per-
formed, and the patch had subsequently calcified and frac-
tured, giving rise to mitral prosthesis dehiscence. Freedom
from reoperation was 93%  4% at 7 years and 90% 
4% at 10 years (Figure 3). Freedom from reoperation was
similar between the native and prosthetic endocarditis
groups (at 7 years, 92%  5% vs 95%  5%; P ¼ .72).
At the latest follow-up, 47 patients were alive, of whom
38 were free from reoperation and were in New York Heart
Association functional class I (27 [71%]), II (7 [18%]), and
III (4 [11%]). Overall event-free survival at 7 and 10 years
was 60%  6% and 47%  7%, respectively, and no dif-
ference was observed between the native and prosthetic
groups (at 7 years, 65%  7% vs 51%  11%; P ¼ .21;
Figure 4). In analyzing the patient and operative characteris-
tics of the prosthetic and native endocarditis groups, the
groups were similar other than a higher incidence of preop-
erative atrial fibrillation (43% vs 12%, P<.001) but a lower
incidence of congestive heart failure (50% vs 84%, P<
.001) and New York Heart Association class IV (72% vs
93%, P ¼ .01) in the patients with prosthetic endocarditis,
respectively. The incidence of abscess was similar in both
groups (prosthetic, 63% vs 45%; P ¼ .1).
We also examined long-term outcomes in patients who had
at least 1 abscess at the time of surgical intervention with those
who had no abscess formation. Paravalvular abscess was asso-
ciated with an operative mortality of 21.7% versus 9.1%
(P¼ .15), and no difference was seen between groups in actu-
arial survival or for freedom from recurrent endocarditis, free-
dom from reoperation, or event-free survival.
Four patients in our series underwent aortic homograft root
replacement. Three of these had concurrent mitral valve repair
and are alive and free from reoperation and recurrent endocar-
ditis at the latest follow-up (longest of 10 years). One patient
FIGURE 2. Long-term actuarial survival for the native versus prosthetic
endocarditis groups.ery c July 2009
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tively from stroke. No patients had mitral homografts.
DISCUSSION
There have been a number of studies that have examined
surgical outcomes after infective endocarditis.4,7,8 We have
previously found that surgical intervention for active endo-
carditis most commonly comprised isolated aortic valve sur-
gery, followed in equal frequency by isolated mitral valve
surgery and double valve (aortic and mitral) surgery.4 There
have, to date, been no reports on the long-term outcomes of
patients with active endocarditis in whom both the aortic and
mitral valves underwent surgical intervention.
We have presented the early and late outcomes of double
valve surgery for active infective endocarditis in a cohort of
90 patients over a 26-year period. A significant mortality
(15.6%) was seen in the short term and also in the longer
term, with a 51%mortality at 10 years. Postoperative recov-
ery was protracted: in our series the mean intensive care unit
stay was 8 days, with a mean hospital stay of 19 days, and
complications were common. One third of late deaths were
valve related, and the incidence of recurrent endocarditis
was 13% in hospital survivors.
TABLE 6. Late morbidity events
Complication No. Died
Endocarditis recurrence 10 6
Thromboembolic events 0
Stroke 2
Transient ischemic attack 3
Reoperations 10 0
Bioprosthetic structural valve deterioration 1
Recurrent endocarditis 3
Perivalvular leak 3
Pannus formation 1
Recurrent mitral regurgitation 2
Perivalvular leak 5 1
Major anticoagulation-related hemorrhage 3 1
Valve thrombosis 1 0
FIGURE 3. Long-term freedom from reoperation for all patients.The Journal of Thoracic andGillinov and colleagues7 from the Cleveland Clinic
reported on the surgical outcomes of 54 patients with native
double valve endocarditis over a 22-year period. There were
no operative mortalities and 9 late deaths, with a 10-year ac-
tuarial survival of 73%. In their series, however, the endo-
carditis was active in only half and remote/healed in the
other half. Patients with active endocarditis tend to be sicker
than those undergoing surgical intervention for healed endo-
carditis, and greater tissue destruction is likely to be encoun-
tered. This makes surgical risk greater in patients with active
endocarditis. The degree of tissue destruction appears to be
more limited in comparison with that seen in our series. Only
11% had abscesses, and there was no contiguous spread be-
tween valves or involvement of the fibrous trigones. By con-
trast, 51% of our patients had abscesses, and intervalvular
fibrous body involvement necessitating patch reconstruc-
tion, a tremendous surgical undertaking, was required in
28%. Gillinov and colleagues7 determined increasing age
and earlier date of operation to be independent predictors
of late death by means of multivariate analysis. We also
identified increasing age as a predictor of late death.
The Cleveland Clinic series was confined to native valve
infection. It is well established that prosthetic valve endocar-
ditis carries a worse outcome than native valve endocardi-
tis.4,9,10 In our study prosthetic endocarditis was associated
with increased operative mortality and was also a significant
independent predictor of late death. Interestingly, there was
no difference between the groups in freedom from recurrent
endocarditis, freedom from reoperation, and event-free sur-
vival, with the latter being a measure of overall morbidity
and mortality in hospital survivors. It appears that the greater
long-term mortality for prosthetic endocarditis relates to the
higher operative mortality and that survivors’ late morbidity
and mortality become similar to that for native endocarditis,
as is evident from Figure 2. This effect appears independent
of the incidence of abscesses because there was no signifi-
cant difference between the native and prosthetic groups
for abscess formation.
FIGURE 4. Event-free survival for the native versus prosthetic groups.Cardiovascular Surgery c Volume 138, Number 1 73
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in 108 surgical patients with active endocarditis and the
presence of an aortic root abscess. Hospital mortality was
17.6%, and they identified, using multivariable analysis,
the need for double valve surgery as strongly predicative
of death, along with female sex, shock, and left ventric-
ular dysfunction or dilatation. They further evaluated 53
patients who underwent operations for aortic valve endo-
carditis with secondary infection of the mitral valve.
Hospital mortality was 26% overall and highest (29%)
in the group requiring aortic root replacement with mitral
valve repair/replacement. Independent predictors of death
were contiguous spread of infection from the aortic to
the mitral valve, whereas jet lesion involvement of the
mitral valve was not a risk factor.
Surgical management of a paravalvular abscess can be
technically challenging. After radical debridement of an
abscess, complex reconstructive surgery might be required.
We have previously found paravalvular abscess to be an
independent predictor of operative mortality in all patients
undergoing surgical intervention for active infective
endocarditis.4 Surgical intervention for endocarditis (of
any valve) complicated by a paravalvular abscess was asso-
ciated with high operative mortality (15.5%) and a 10-year
actuarial survival of 57%.12 In our current study almost half
the patients undergoing double valve surgery for active en-
docarditis had at least 1 abscess, and frequently multiple ab-
scesses were present. In keeping with our previous work,
a paravalvular abscess was again found to be associated
with high operative mortality (21.7%), although this did
not reach statistical significance (P ¼ .15).
It is not surprising that highly complex operations might
be necessary in patients with active endocarditis in whom
both the aortic and mitral valves require intervention. Aortic
root replacement was performed in 12 patients, 4 with a ho-
mograft. Ten of these patients had aortic root abscesses,
sometimes enveloping the coronary arteries, which required
modified Cabrol interposition grafts to reattach the coronary
arteries. Double valve replacement with reconstruction of
the intervalvular fibrous body was performed in 25 patients,
19 of whom had abscess formation. Remarkably, such com-
plex procedures were not associated with increased opera-
tive mortality nor were they predictors of long-term death.
It is noteworthy that in this series early redo operations (ie,
within the same hospital admission) were required in 6
(6.7%) patients. This is indicative of the extent of tissue de-
struction that was seen and the complexity of reconstruction
that was required. Although there is much discussion regard-
ing the use of homografts in active endocarditis,13,14 we
would emphasize that homograft use does not substitute
for the principle of radical debridement with appropriate re-
construction. Mitral homograft use is rare,15 and no benefit is
obtained by performing aortic homograft replacement if
a stented mitral prosthesis is used.74 The Journal of Thoracic and Cardiovascular SurgIn addition to increasing age and prosthetic endocarditis,
preoperative shock and diabetes mellitus were independent
predictors of death from all causes. Preoperative shock is
well documented as being an independent risk factor for op-
erative and late death.4,11,12,16 Diabetes mellitus is increas-
ingly being identified as a risk factor for in-hospital
mortality in patients with infective endocarditis who are
medically treated,17-19 as well as those undergoing surgical
intervention.16,20 A French prospective population-based
survey found insulin-dependent diabetes mellitus to be an
independent predictor of in-hospital death (odds ratio,
7.82) in 559 cases of definite infective endocarditis.18 Sub-
analysis demonstrated insulin-dependent diabetes to be as-
sociated with greater mortality (50% vs 19%) than oral
medication–treated diabetes and remained predictive of
death, whereas the latter was not predictive of death.19
Rosamel and coworkers20 noted diabetes mellitus to be
associated with increased operative mortality in 98 patients
undergoing surgical intervention for active endocarditis of
any valve. Of 6627 patients in a large retrospective review
of the Society of Thoracic Surgeons National Cardiac Data-
base, Gammie and colleagues16 found diabetes to be an
independent predictor of operative mortality when examin-
ing outcomes of surgical intervention for mitral valve endo-
carditis (odds ratio, 1.59), although only 40% of the cohort
had active endocarditis. To the best of our knowledge, this is
the first report that demonstrates diabetes to be an indepen-
dent predictor of long-term death after surgical intervention
for endocarditis.
In summary, we have presented the early and late
outcomes of double valve surgery for active infective endo-
carditis. Double valve surgery is a substantial undertaking in
the setting of active endocarditis. Operative mortality and
perioperative morbidity are significant, but reasonable
long-term survival can be achieved. Good freedom from
reoperation and recurrent endocarditis are seen. Survival is
worse in patients with prosthetic valve endocarditis, but
hospital survivors attain event-free survival comparable
with that of patients with native valve endocarditis.
References
1. d’Udekem Y, David TE, Feindel CM, Armstrong S, Sun Z. Long-term results of
surgery for active infective endocarditis. Eur J Cardiothorac Surg. 1997;11:46-52.
2. David TE, Komeda M, Brofman PR. Surgical treatment of aortic root abscess.
Circulation. 1989;80:I269-74.
3. David TE, Feindel CM, Armstrong S, Sun Z. Reconstruction of the mitral anulus.
A ten-year experience. J Thorac Cardiovasc Surg. 1995;110:1323-32.
4. David TE, Gavra G, Feindel CM, Regesta T, Armstrong S, Maganti MD. Surgical
treatment of active infective endocarditis: a continued challenge. J Thorac
Cardiovasc Surg. 2007;133:144-9.
5. David TE, Kuo J, Armstrong S. Aortic and mitral valve replacement with recon-
struction of the intervalvular fibrous body. J Thorac Cardiovasc Surg. 1997;114:
766-71.
6. Akins CW, Miller DC, Turina MI, Kouchoukos NT, Blackstone EH,
Grunkemeier GL, et al. Guidelines for reporting mortality and morbidity after
cardiac valve interventions. Ann Thorac Surg. 2008;85:1490-5.
7. Gillinov AM, Diaz R, Blackstone EH, Pettersson GB, Sabik JF, Lytle BW, et al.
Double valve endocarditis. Ann Thorac Surg. 2001;71:1874-9.ery c July 2009
A
C
D
Sheikh et al Acquired Cardiovascular Disease8. Kaiser SP, Melby SJ, Zierer A, Schuessler RB, Moon MR, Moazami N, et al.
Long-term outcomes in valve replacement surgery for infective endocarditis.
Ann Thorac Surg. 2007;83:30-5.
9. Wang A, Pappas P, Anstrom KJ, Abrutyn E, Fowler VG Jr, Hoen B, et al. The use
and effect of surgical therapy for prosthetic valve infective endocarditis: a propen-
sity analysis of a multicenter, international cohort. Am Heart J. 2005;150:
1086-91.
10. Wang A, Athan E, Pappas PA, Fowler VG Jr, Olaison L, Pare C, et al. Contem-
porary clinical profile and outcome of prosthetic valve endocarditis. JAMA. 2007;
297:1354-61.
11. Siniawski H, Grauhan O, Hofmann M, Pasic M, Weng Y, Yankah C, et al. Aortic
root abscess and secondary infective mitral valve disease: results of surgical endo-
carditis treatment. Eur J Cardiothorac Surg. 2005;27:434-40.
12. David TE, Regesta T, Gavra G, Armstrong S, Maganti MD. Surgical treat-
ment of paravalvular abscess: long-term results. Eur J Cardiothorac Surg.
2007;31:43-8.
13. Hagl C, Galla JD, Lansman SL, Fink D, Bodian CA, Spielvogel D, et al. Replac-
ing the ascending aorta and aortic valve for acute prosthetic valve endocarditis: is
using prosthetic material contraindicated? Ann Thorac Surg. 2002;74(suppl):
S1781-5.The Journal of Thoracic and14. Sabik JF, Lytle BW, Blackstone EH, Marullo AG, Pettersson GB, Cosgrove DM.
Aortic root replacement with cryopreserved allograft for prosthetic valve endocar-
ditis. Ann Thorac Surg. 2002;74:650-9.
15. Obadia JF, Henaine R, Bergerot C, Ginon I, Nataf P, Chavanis N, et al. Monobloc
aorto-mitral homograft or mechanical valve replacement: a new surgical option for
extensive bivalvular endocarditis. J Thorac Cardiovasc Surg. 2006;131:243-5.
16. Gammie JS, O’Brien SM, Griffith BP, Peterson ED. Surgical treatment of mitral
valve endocarditis in North America. Ann Thorac Surg. 2005;80:2199-204.
17. Chu VH, Cabell CH, Benjamin DK Jr, Kuniholm EF, Fowler VG Jr, Engemann J,
et al. Early predictors of in-hospital death in infective endocarditis. Circulation.
2004;109:1745-9.
18. Delahaye F, Alla F, Beguinot I, Bruneval P, Doco-Lecompte T, Lacassin F, et al.
In-hospital mortality of infective endocarditis: prognostic factors and evolution
over an 8-year period. Scand J Infect Dis. 2007;39:849-57.
19. Duval X, Alla F, Doco-Lecompte T, Le Moing V, Delahaye F, Mainardi JL, et al.
Diabetes mellitus and infective endocarditis: the insulin factor in patient morbidity
and mortality. Eur Heart J. 2007;28:59-64.
20. Rosamel P, Cervantes M, Tristan A, Thivolet-Bejui F, Bastien O, Obadia JF, et al.
Active infectious endocarditis: postoperative outcome. J Cardiothorac Vasc
Anesth. 2005;19:435-9.Cardiovascular Surgery c Volume 138, Number 1 75
